MediMap Bio (Co-CEOs Kang Yu-hoe and Cho Hong-seok) , a company specializing in immunotherapy, announced on the 27th that it has completed securing a Series B investment totaling 25.6 billion won.
This round of investment saw the participation of six existing investors, KB Investment, Smilegate Investment, BNH Investment, Hyundai Investment Partners, IM Investment Partners, and Timefolio Asset Management, as follow-up investors. Eight new investors, Yuanta Investment, Seoul Investment Partners, Snickpick Investment, Union Investment Partners, Aion Investment, E&Venture Partners, Dongbang FT, and HLB Biostep, joined the round. A total of 14 institutions participated in this round.
MediMap Bio is a company developing autoimmune disease treatments and immuno-oncology drugs based on its proprietary fusion antibody platform technology, MediLink™. Founded by co-CEOs Kang Yu-hoe and Cho Hong-seok, both from the Samsung Advanced Institute of Technology, MediMap Bio possesses the technology to precisely control immune signaling by fusing antibodies with immune-modulating cytokines.
The main pipeline, MFA031, is a therapeutic that combines an antibody targeting an immune receptor with a next-generation immune-regulatory cytokine, aiming to restore immune balance in various inflammatory diseases such as autoimmune diseases and organ transplant rejection.
This investment will be used to advance the commercialization of MFA031, develop follow-up pipelines, and expand global technical collaborations. The company plans to accelerate the commercialization of autoimmune disease treatments and accelerate its entry into the global market.
Kang Yoo-hoe, CEO of MediMap Bio, said, “Through this investment, we will strengthen our partnerships with global pharmaceutical companies and accelerate the research, development, and commercialization of next-generation immunotherapies.”
- See more related articles
You must be logged in to post a comment.